Central nervous system: Headache (6% to 9%), fatigue (dose-related; 2% to 5%), dizziness (2% to 4%), insomnia (1%), paresthesia.
Dermatologic: Skin rash (≤ 1%).
Endocrine & metabolic: Decreased HDL cholesterol, hypercholesterolemia, increased serum triglycerides, increased uric acid.
Gastrointestinal: Diarrhea (dose-related; 2% to 3%), nausea (1% to 3%), abdominal pain.
Hematologic & oncologic: Decreased platelet count.
Neuromuscular & skeletal: Weakness.
Renal: Increased blood urea nitrogen.
Respiratory: Dyspnea (≤ 1%).
≤ 1%, postmarketing, and/or case reports: Acute pulmonary edema, acute renal failure, angioedema, atrioventricular block (second and third degree), bronchospasm, claudication, dermatological disease, drowsiness, erectile dysfunction, hepatic insufficiency, hypersensitivity angiitis, hypersensitivity reaction, increased serum ALT, increased serum AST, increased serum bilirubin, myocardial infarction, peripheral ischemia, pruritus, psoriasis, Raynaud's phenomenon, syncope, thrombocytopenia, urticarial, vertigo, vomiting.
View ADR Monitoring Form